# Pay a prize for rare cancer drugs instead of hoping for a market

Source: https://onco.cc/ideas/idea-bio2-rare-cancer-prize-fund/  
OnCo record `idea-bio2-rare-cancer-prize-fund` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

No company can profit from a drug for a cancer that affects a few hundred people. A guaranteed payment for success would change that calculation.

## Summary

Rare and paediatric cancers lack markets, and existing incentives (orphan designation, priority review vouchers, the proposed transferable exclusivity vouchers) are criticised for poor targeting and high cost to payers. A directly funded prize or advance market commitment, paid on achieving a pre-specified clinical benefit in a named rare indication, targets the payment to the outcome and avoids distorting prices elsewhere.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A pooled prize fund of a few hundred million dollars, with clearly specified indication targets and evidence thresholds, attracts at least five serious development programmes into rare cancers within five years, at lower total public cost than voucher schemes.
- Rationale: Advance market commitments worked for pneumococcal vaccines, and prize mechanisms have produced results in other fields. Vouchers transfer cost opaquely to payers of unrelated drugs, whereas a prize is explicit and can be targeted at the exact unmet need.
- Proposed test: Model the cost of existing voucher schemes against an equivalent prize fund, then have one government or philanthropic consortium commit a single named prize for one rare indication and observe how many programmes enter.
- Maturity: speculative
- Actor: policy

## Sources

- EMA orphan designation: https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- bottlenecks: [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-rare-cancer-prize-fund.json